You can buy or sell BPMC and other stocks, options, ETFs, and crypto commission-free!
Blueprint Medicines Corporation Common Stock, also called Blueprint Medicines, is a precision therapy company, which focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Read More Lydon, Brian Druker, and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Seeking AlphaFeb 25
Blueprint Medicines Q4 2018 Earnings Preview
Blueprint Medicines (NASDAQ:BPMC) is scheduled to announce Q4 earnings results on Tuesday, February 26th, before market open. The consensus EPS Estimate is -$1.76 (-43.1% Y/Y) and the consensus Revenue Estimate is $1.69M (+3.7% Y/Y). Over the last 2 years, BPMC has beaten EPS estimates 63% of the time and has beaten revenue estimates 88% of the time....
Expected May 1, Pre-Market